Allergy and Colorectal Cancer Awareness Month
Promotional packages from Kandilarov Laboratory
Valid from April 1 to April 30
Take care of your health this month with our special promotions!
Choose from allergy packages and take advantage of great prices.
Panel Exema
(10 allergen IgE)
House dust mite, Cat’s epithelium, Dog’s epithelium, Latex, Egg white, Cod (fish), Soy, Cocoa (chocolate), Hazelnut, Peanut
Price: 72 lv. 60 BGN.
Panel Insects
(5 allergen IgE)
Bee Venom, Wasp Venom, Hornet Venom, Mosquito, Flies
Price: 72 lv. 60 BGN.
Food Allergens Panel
(30 allergen IgE)
Tomato, Avocado, Banana, Citrus Mix (Lemon , Lime, Orange , Tangerine), Kiwi, Peanut, Hazelnut, Pea, Soy, Celery, Beef, Chicken, Pork, Mussel, Prawn, Crab, Yellowfin tuna, Cod, Garlic, Onion, Breadfruit, Sesame, Rice, Corn, Wheat flour Alpha (lactalbumin), Beta (lactoglobulin), Casein, Egg white
Price: 115 BGN 105 BGN
Allergy to milk and gluten
(IgE antibodies)
Price: 69 BGN 59 lv.
Allergic atopic panel
(IgE antibodies)
Price: 88 BGN 88 BGN.
Allergic Pediatric Panel
(IgE antibodies – adults and children)
Price: 78 lv. 78,50 BGN
Panel of 10 inhaled allergens
(IgE antibodies)
Price: 72 lv. 62 BGN.
Panel of 30 inhaled allergens
(IgE antibodies)
Price: 115 BGN 105 BGN
Combination test for allergies to 295 allergens
ALEX ALLERGY EXPLORER
Price: 395 BGN 385 BGN
Combined allergy test to 295 allergens and Candida albicans IgG test
295 allergen – ALEX ALLERGY EXPLORER
Price: 405 BGN 405 lv.
Combined allergy test to 295 allergens and Candida albicans IgG + IgM testing
295 allergen – ALEX ALLERGY EXPLORER
Price: 420 BGN 409 BGN
Package Vitamins and trace elements
VITAMIN D, VITAMIN B12, GELATIN /Fe/, CALCIUM /Ca/, IONIZED CALCIUM /Ca++/, MAGNESIUM /Mg/, ZINC/Zn/, SELENIUM /Se/, IODINE/, HONEY /Cu/
Price: 231,40 BGN 170 BGN.
Research for Helicobacter pylori
Helicobacter pylori IgA;
Helicobacter pylori IgG;
Helicobacter pylori antigen in feces.
Price: 82 BGN 82 82 BGN
COLON CANCER PREVENTION
Colon tumor marker
19-9 AND OCCULT BLOOD TEST /FECES/
Price: 31 BGN 31 BGN.
ColoAlert – colon cancer screening test kit
ColoAlert is a colon cancer screening test. This kit is used to collect stool samples from the patient.
Price: 420 BGN 390 lv.
Promotional price until the end of APRIL 2025.
Gene testing for cancer
֍ Cancer Molecular Tests
HerediGENE®
Price:
|
|
|---|---|
| Description | HerediGENE® is a diagnostic multigene test for hereditary cancer that analyzes 52 genes, 21 of which are associated with homologous recombination (including BRCA 1/2). These genes are involved in the increased risk of breast, ovarian, prostate, colorectal and other hereditary cancers. Advanced next-generation sequencing (NGS) technology is used.
The test can be used as a tool for prevention, providing correct information to the physician about personal treatment of the patient or to identify family members predisposed to cancer. |
| Types of cancer | Breast, colorectal, prostate, pancreas, ovarian, stomach, melanoma, thyroid, kidney, endometrium |
| Cancer syndromes | Hereditary breast and ovarian cancer syndrome, Lynch syndrome, Cowden syndrome, Li-Fraumeni syndrome, Peutz-Jeghers syndrome, familial adenomatous polyposis, Von-Hippel Lindau syndrome, multiple endocrine neoplasia, others. |
| Possible results |
|
| Who is the HerediGENE® test suitable for? |
|
| Additional information | The results are useful for the whole family, as it is enough for a person to inherit a mutation from one parent to have an increased risk of developing cancer. Any individual whose parent carries the mutation has a 50% chance of inheriting the mutation. More distant relatives are also at risk of carrying the mutation.
Note that inherited susceptibility syndromes can be associated with many different types of cancer. Therefore, a mutation found in a breast or ovarian cancer sample may be associated with an increased risk of pancreatic or prostate cancer. |
| Time limit for obtaining the result | 20 working days |
| What type of sample is needed for the test? | Blood sample with EDTA (2 tubes) or saliva in a special kit supplied by our company. |
Com.pl.i.t DX® Colon
Price:
|
|
|---|---|
| Description | The Com.pl.it DX® Colon multigene test includes gene mutations associated with colorectal cancer. Analysis of many of these are essential to design a personalized treatment plan for patients. |
| How does the Com.Pl.it DX® test help in choosing the right treatment? |
|
| Immunotherapeutic biomarkers | MSI |
| Immunohistochemical biomarkers (IHC) | HER2 |
| Time limit for obtaining the result | 10 working days |
| What type of sample is needed for the test? | Tumour block |
| Panel with 27 Gene Mutations | ||
|---|---|---|
| AKT1 | ALK | BRAF |
| CDKN2A | CTNNB1 | DDR2 |
| EGFR | ERBB2 | FBXW7 |
| FGFR1 | FGFR2 | FGFR3 |
| HRAS | KEAP | KRAS |
| MAP2K1 | MET | NOTCH1 |
| NRAS | PIK3CA | POLE |
| PTEN | RET | SMAD4 |
| SMARCA4 | STK11 | TP53 |
| TP53 | ||
| 7 Gene rearrangements | |
|---|---|
| ALK | MET |
| ROS1 | RET |
| NTRK1 | NTRK2 |
| NTRK3 | |
prime DX®
Price:
|
|
|---|---|
| Description | The new prime DX® molecular tumor profiling technology is compatible with both FFPE and PLASMA!
It is one of the most detailed, sensitive, and specific tests for tumor biology configuration, allowing physicians to plan effective cancer treatments for the patient, including targeted therapies, immunotherapy, chemotherapy, PARP inhibitors, and compatibility with clinical trial participation. It provides answers regarding the toxicity of chemotherapy drugs, such as 5-FU, irinotecan, and others. |
| The test can be used in the following cases |
In addition,
|
| Why choose prime DX® | Choosing the most appropriate cancer treatment: proven to provide more useful information than any other test. By analyzing 1,021 unique cancer genes and the immunotherapy biomarkers MSI, PD-L1, LOH (for ovarian cancer), HLA and TMV, the prime DX® test provides access to the largest amount of useful information to date, providing the clearest indication to the physician of which targeted therapies will and will not benefit the patient, including immunotherapy, chemotherapy and PARP inhibitors.
Continuous support for the doctor and the patient by an experienced team. The procedure of the prime DX® test or any other test at Genekor Medical S.A. does not end with the notification of the results. Experienced customer service and scientific consulting teams work with the physician and patient throughout the entire process. Highly accurate, sensitive and reliable technology: based on advanced hybrid detector enrichment technology of targeted genomic regions. In addition, it uses molecular trackers (UMI) for increased sensitivity in detecting somatic variants. |
| Results | The prime DX® assay results include a detailed explanation of all findings, including the following information:
|
| You can add the following immunohistochemical markers |
|
| Time limit for obtaining the result | 15 working days |
| What type of sample is needed for the test? | Tumour block |
Prime DX is an NGS panel of 1021 genes, of which 36 are HR genes.
The test also includes:
| Immunotherapeutic biomarkers | PARP inhibitors biomarkers | IHC Biomarkers |
|---|---|---|
| TMB | LOH | PD-L1 |
| MSI | HER2 | |
| HLA | FRα | |
| CLDN18.2 |
| Agnostic markers | |
|---|---|
| Targeted therapies | Immunotherapies |
| NTRK1,2,3 | TMB |
| RET Fusions | MSI |
| BRAFV600E Mutation | |
| HER2 Amplification | |
prime DX® Liquid
Price:
|
|
|---|---|
| Description | The new prime DX® Liquid assay consists of a panel of 1021 genes, analyzing the immunotherapeutic biomarkers TMB, MSI, HLA, allowing the treating physician to plan effective treatment, including immunotherapy, chemotherapy, PARP inhibitors and compatibility for participation in clinical trials.
In addition, prime DX® Liquid analyzes genes associated with genetic susceptibility to cancer, thus providing the physician with information about the likelihood of hereditary cancer. |
| Recommended for the following cases |
|
| Advantages of liquid biopsy |
|
| Results | The prime DX® Liquid assay results include a detailed explanation of all findings, including the following information:
|
| Time limit for obtaining the result | 15 working days |
| What type of sample is needed for the test? | Blood sample in a special tube provided by the company (Cell-Free DNA BCT®(10ml)) |
MyWES®
Price:
|
|
|---|---|
| Description | The test is based on Whole Exome Sequencing (WES) and performs a complete screening of more than 20,000 genes to detect and diagnose genetic diseases.
Most of the genetic variants responsible for disease are found in the coding exons of the human genome. They make up only 1% – 2% of the genome, but in total 85% of all known mutations are thought to be located in these regions. For this reason, it makes sense to perform targeted WES analysis. MyWES® can be done during pregnancy, childhood or adulthood. |
| When is the diagnostic test recommended? |
|
| When is the prophylaxis test recommended? |
|
| Time limit for obtaining the result | 25 working days |
| Sample required | EDTA blood sample (2 tubes) |
Clinkor®
Price:
|
|---|
| Clinkor® | |
|---|---|
| Description | The Clinkor® test is based on the analysis of more than 5,000 clinically important genes associated with inherited diseases. It can have great diagnostic value in cases of rare diseases or in cases of indeterminate phenotype. |
| When is it recommended for diagnosis? |
|
| Technical information | Clinical exome testing is performed using next-generation sequencing (NGS) technology. A patient’s blood DNA sample is compared to a reference sequence (representing the ‘normal’ human DNA sequence) in an attempt to identify differences between the two. If there are differences, they are reviewed by our expert laboratory geneticists and your physician to classify the findings and determine their pathogenesis. |
| Time limit for obtaining the result | 25 working days |
| What type of sample is needed for the test? | Blood sample with EDTA (2 tubes) |
Advantages of tumour DNA analysis
Early in the development of colorectal cancer, there are somatic – i.e. acquired during life – mutations in the genome of intestinal cells. As the cells of the intestinal mucosa are continuously removed in the stool, their DNA can be detected in the stool using PCR.
For diagnosis, the ColoAlert lab first separates human DNA from DNA from other sources, such as gut bacteria and food. It then quantifies the total amount of human DNA . In the case of tumors – but also in the case of inflammatory processes – the total amount of human DNA in the stool increases noticeably. In a next step, the laboratory tests the DNA for common KRAS and BRAF gene mutations.
KRAS gene mutation
The KRAS gene (K-RAS gene) encodes the K-Ras protein of the same name, which regulates cell growth and cell division as a molecular switch. To do this, it switches between active and inactive states. If there are mutations in the KRAS gene, the K-Ras protein is always active. This leads to uncontrolled cell division and the tumour grows uncontrollably.
About one in three tumours has a mutation in one of the RAS genes. This applies in particular to colon and exocrine pancreatic carcinomas. Because the mutations involved are somatic, ColoAlert is not a genetic test in the conventional sense.
The frequent involvement of the K-Ras protein in tumorigenesis also makes it an important therapeutic target. For example, researchers have been able to find an inhibitor that disrupts KRAS transport to the cell membrane and thus significantly reduces tumor growth. This is yet another reason why the detection of a mutation in the KRAS gene is a plus for ColoAlert colorectal cancer diagnostics.
BRAF gene mutation
The BRAF gene (B-RAF gene) encodes a special protein kinase, the serine/threonine kinase B-Raf, which also regulates an important signaling pathway for cell division and differentiation. Mutations in the BRAF gene can permanently activate the signalling pathway and thus contribute to the development of colorectal cancer, for example.
The BRAF V600 mutation, which causes fast-growing and aggressive tumours, is particularly common in tumour cells. About 8 to 10 percent of all patients with metastatic colorectal cancer are affected.
BRAF inhibitors can block the signaling pathway and thus induce apoptosis of tumor cells.
How reliable is the ColoAlert test?
Analyzing these biomarkers, ColoAlert achieves a sensitivity of 85% and a specificity of 92%. As with any diagnostic procedure, both false negative and false positive test results can occur.
What should I do in case of a positive result?
In the event of a positive test result, no therapeutic measures should be taken without prior consultation with the treating therapist.
Important – how to prepare for the study?
A biological fecal sample is provided for laboratory analysis. It is recommended not to take antibiotic and probiotic medications in the 2-week period prior to its collection, as they may interfere with the examination.
Related articles
NATIONAL CAMPAIGN “THYROID AND ARTIFICIAL INTELLIGENCE” ...
24.05.2025
Month At Prevention в Laboratory Kandilarov Find Promotional us research и special packages, Created...
02.05.2025
WOMEN'S MONTH SPECIAL PROMOTIONS Promotional packages from Kandilarov Laboratory Valid from 1 to...
01.03.2025
Experts advise
Depression, burnout and anxiety are among the greatest challenges of our time. How to...
24.04.2025
Is obesity dangerous? Why is early diagnosis important and when to take action? In...
24.04.2025
Is obesity dangerous? Why is early diagnosis important and when to take action? In...
22.04.2025
